A Vaccine for lyme disease: Current progress

Infections in Medicine

Volumn 15, Issue 1, 1998, Pages 40-42

  Golde, William T ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Borrelia burgdorferi; Lyme disease; Vaccination

Indexed keywords

VACCINE;

BORRELIA BURGDORFERI; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LYME DISEASE; NORTH AMERICA; REVIEW; UNITED STATES;

EID: 0031961040     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Centers for Disease Control and Prevention: Lyme disease, United States, 1991 and 1992. MMWR 42:345-348, 1994.
2. Burgdorfer W, Barbour A, Hayes S, et al: Lyme Disease - A tick-borne spirochetosis? Science 216:1317-1319, 1982.
3. Steere A, Malawista S, Snydman D, et al: Lyme arthritis: An epidemic of oligoarticular arthritis in children and adults in these Connecticut counties. Arthritis Rheum 20:7-17, 1977.
4. Lane R, Piesman J, Burgdorfer W: Lyme borreliosis: Relation of the causative agent to its vectors and hosts in the North America and Europe. Annu Rev Entomol 36:587-609, 1977.
5. Burgdorfer W, Lane R, Barbour A, et al: The western black-legged tick, Ixodes pacificus, a vector of B burgdorferi. Am J Trop Med Hyg 34:925-930, 1985.
6. Burnet LR, Sellito C, Spielman A, et al: Antibody response of the mouse reservoir host of Borrelia burgdorferi in nature. Infect Immun 63:3030-3036, 1995.
7. Golde WT, Burkot TR, Sviat S, et al: The MHC restricted response of recombinant inbred strains of mice to natural tick transmission of B burgdorferi. J Exp Med 177:9-17, 1993.
8. Schaible UE, Wallich, R, Kramer MD, et al: Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of a different OspA/ OspB genotype. Vaccine 11(10):1049-1054, 1993.
9. DeFosse DL, Duray PH, Johnson RC: The NIH-3 immunodeficient mouse is a model for Lyme borreliosis myositis and carditis. Am J Pathol 141:3-9, 1992.
10. Barthold SW, Beck DS, Hansen GM, et al: Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis 162:133-138, 1990.
11. Schaible UE, Kramer MD, Wallich R, et al: Experimental Borrelia burgdorferi infection in inbred mouse strains: Antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol 21:2397-2405, 1991.
12. Barbour AG, Tessier SL, Todd WJ: Lyme disease spirochetes and Ixodid tick spirochetes share a common surface antigen determinant defined by a monoclonal antibody. Infect Immun 41:795-804, 1983.
13. Kramer MD, Schaible UE, Wallich R, et al: Characterization of Borrelia burgdorferi associated antigens by monoclonal antibodies. Immunobiology 181:357-366, 1990.
14. Schubach WH, Mudri S, Dattwyler RJ, et al: Mapping antibody binding domains of the major outer surface protein (OspA) of Borrelia burgdorferi. Infect Immun 59:1911-1915, 1991.
15. Wilske B, Luft B, Shubach WH, et al: Molecular analysis of the outer surface protein A (OspA) of Borrelia burgdorferi for conserved and variable antibody binding domains. Med Microbiol Immun 181:191-207, 1992.
16. Howe TR, Mayer LW, Barbour AG: A single recombinant plasmid expressing two major outer surface proteins of the Lyme disease spirochete. Science 227:645-646, 1985.
17. Wallich R, Schaible UE, Simon MM, et al: Cloning and sequencing of the gene encoding the outer surface protein A (OspA) of a European Borrelia burgdorferi isolate. Nucleic Acids Res 17: 8864, 1992.
18. Dunn JJ, Lade BN, Barbour AG: Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: High level expression and purification of a soluble recombinant form of OspA. Protein Expr Purif 1:159-168, 1990.
19. McGrath BC, Dunn JJ, Gorgone G, et al: Identification of an immunologically important hypervariable domain of the major outer surface protein A of Borrelia burgdorferi. Infect Immun 63(4):1356-1361, 1995.
20. Wilske B, Abarbour AG, Bergstrom S, et al: Antigenic variation and strain heterogeneity in Borrelia spp. Res Microbiol 143:583-596, 1992.
21. Bergstrom S, Bundoc VG, Barbour AG: Molecular analysis of linear plasmid encoded major surface proteins OspA and OspB of the Lyme disease spirochete, Borrelia burgdorferi. Mol Microbiol 3:479-486, 1989.
22. Baranton G, Postic D, Saint-Girons I, et al: Delineation of Borrelia burdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme disease. Int J Systemic Bacteriol 42:378-383, 1992.
23. Welsh J, Pretzman C, Postic D, et al: Genomic fingerprinting by arbitrarily primed polymerase chain reaction resolves Borrelia burgdorferi into three distinct phyletic groups. Int J Systemic Bacteriol 42:370-377, 1992.
24. Masuzawa T, Suzuki H, Kawabata H, et al: Identification of spirochetes isolated from wild rodents in Japan as Borrelia japonica. J Clin Microbiol 33:1392-1394, 1995.
25. Fikrig E, Barthold SW, Kantor FS, et al: Protection of mice against the Lyme Disease agent by immunizing with recombinant OspA. Science 250:553-556, 1990.
26. Simon MM, Schaible UE, Krammer MD, et al: Recombinant outer surface protein A (OspA) from Borrelia burgdorferi induces protective antibodies against spirochetal infection in mice. J Infect Dis 164:123-132, 1991.
27. Luke CJ, Carner K, Liang X, et al: An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 175:91-97, 1997.
28. Barthold SW, Fikrig E, Bockenstadt LK, et al: Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect Immun 63:2255-2261, 1995.
29. Pachner AR, Delaney E, Ricalton N: Murine Lyme borreliosis: Route of innoculation determines immune response and infectivity. Reg Immunol 4:345-351, 1992.
30. Golde WT, Dolan MC: Variation in antigenicity and infectivity of Borrelia burgdorferi strain B31 maintained in natural, zoonotic cycle compared to culture. Infect Immun 63:4795-4801, 1995.
31. Appel MJ, Allan S, Jacobson RH, et al: Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis 167:651-664, 1993.
32. Golde WT, Burkot TR, Sviat S, et al: The major histocompatibility complex-restricted response of recombinant inbred strains of mice to natural tick transmission of Borrelia burgdorferi. J Exp Med 177:9-17, 1993.
33. Golde WT, Kappel KJ, Capiau C, et al: Tick transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response to P39 but not outer surface protein A (OspA). Infect Immun 62:2625-2627, 1994.
34. De Silva AM, Fikrig E: Growth and migration of Borrelia burgdorferi in Ixodes ticks during blood feeding. Am J Trop Med Hyg 53:397-404, 1995.
35. Schwan TG, Piesman J, Golde WT, et al: Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A 92:2909-2913, 1995.
36. Kalish RA, Leong J, Steere AC: Association of treatment resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity with OspA and OspB of Borrelia burgdorferi. Infect Immun 61:2774-2779, 1993.
37. Fikrig E, Telford SR, Barthold SW, et al: Elimination of Borrelia burgdorferi from ticks feeding on OspA immunized mice. Proc Natl Acad Sci U S A 89:5418-5421, 1992.
38. Telford SR, Kantor FS, Lobet Y, et al: Efficacy of human Lyme disease vaccine formulations in a mouse model. J Infect Dis 171:1368-1370, 1995.
39. Golde WT, Burkot TR, Piesman J, et al: The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of burgdorferi. Vaccine 13:435-441, 1995.
40. Gern L, Rais O, Capiau C, et al: Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus ticks. Immunol Lett 39:249-258, 1994.
41. Johnson BJ, Sviat SL, Happ CM, et al: Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13:1086-1094, 1995.
42. Chang YF, Appel MJ, Jacobson RH, et al: Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 63:3543-3549, 1995.
43. Phillip MT, Lobet Y, Bohm RP, et al: Safety and immunogenicity of recombinant outer surface protein A (OspA) vaccine formulations in the Rhesus monkey. J Spirochetal Tick-Borne Dis 3:1-13, 1996.
44. Bokenstedt LK, Fikrig E, Barthold SW, et al: Inability of recombinant OspA to elicit protective immunity to Borrelia burgdorferi in mice. J Immunol 151:900-906, 1993.
45. Golde WT, Piesman J, Dolan MC, et al: Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 65:882-889, 1997.
46. Telford SR, Fikrig E, Barthod SW, et al: Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J Exp Med 178:755-758, 1993.
47. Van Hoecke C, Comberbach M, De Grave D, et al: Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine 14:1620-1626, 1996.
48. Zhang YQ, Mathiesen D, Kolbert CP, et al: Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection. J Clin Microbiol 35:233-238, 1997.
49. Persing DH: The cold zone: A curious convergence of tick-transmitted diseases. Clin Infect Dis 25(5):35-42, 1997.